The Medicines Patent Pool Foundation

Governance Board Meeting Chairman’s Summary
19th February 2015

Teleconference
Attendees: Board Members: Dr. Charles Clift, Dr. Bernard Pécoul, Dr. Sigrun Møgedal, Dr. Anban Pillay, Ms. Anna Żakowicz

MPP staff: Greg Perry (Executive Director), Chan Park (General Counsel), Sandeep Juneja (Business Director), Esteban Burrone (Head of Policy), Katie Moore (Head of Communications), Alnaaze Nathoo (Operations and Strategy Manager) and Asma Rehan (Operations Officer).

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and Merck, Sharp and Dome (MSD) on pediatric raltegravir (RAL).

The Board has reviewed the EAG report assessing the Licence Agreement between the MPP and MSD. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes and Memorandum of Understanding with UNITAID, and represents a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with MSD to formalise the collaboration. The Board further recommends that the MPP seek to expand the relationship with MSD to include the licensing of adult formulations of MSD products.